— Know what they know.
Not Investment Advice
Also trades as: 0HD2.L (LSE) · $vol 0M · DUL.DE (XETRA) · $vol 0M

ALNY NASDAQ

Alnylam Pharmaceuticals, Inc.
1W: +2.4% 1M: -3.2% 3M: -10.6% YTD: -24.9% 1Y: +3.0% 3Y: +57.4% 5Y: +121.5%
$297.45
-3.06 (-1.02%)
 
Weekly Expected Move ±4.3%
$262 $275 $287 $299 $312
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 46 · $39.7B mcap · 133M float · 0.822% daily turnover · Short 46% of daily vol

📊 Key Metrics

TTM
$4B
Revenue
+82.6% YoY
$577M
Net Income
+314.0% YoY
$641M
Free Cash Flow
+950.8% YoY
81.9%
Gross Margin
23.0%
Op. Margin
17.6%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE134.8%
ROA12.5%
ROIC-92.8%

Valuation

P/E68.5
P/B36.8
EV/EBITDA71.9

Leverage

Debt/Equity1.62
Current Ratio2.76
Interest Cov.2.0x

Quality Scores

Piotroski F6/9
Altman Z6.55
Beneish M-1.75

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms